ES2120993T3 - Agentes antitromboticos. - Google Patents

Agentes antitromboticos.

Info

Publication number
ES2120993T3
ES2120993T3 ES92310292T ES92310292T ES2120993T3 ES 2120993 T3 ES2120993 T3 ES 2120993T3 ES 92310292 T ES92310292 T ES 92310292T ES 92310292 T ES92310292 T ES 92310292T ES 2120993 T3 ES2120993 T3 ES 2120993T3
Authority
ES
Spain
Prior art keywords
alcoil
antithrombotic agents
inhibitors
fenilglicilo
fenilalanilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92310292T
Other languages
English (en)
Inventor
Robert Theodore Shuman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2120993T3 publication Critical patent/ES2120993T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INHIBIDORES DE TROMBINA REPRESENTADOS POR LA FORMULA TAL COMO SE ESPECIFICA DONDE A ES POR EJEMPLO FENILGLICILO, Y FENILALANILO, (ALFA) INA DONDE EL GRUPO AMINO ESTA PREFERENTEMENTE SUSTITUIDO POR ALCANOIL ALQUILO INFERIOR O ALCOXICARBONILO INFERIOR, O UN GRUPO BICICLO POR EJEMPLO 1,2,3,4 TAMBIEN SE MUESTRA UN METODO PARA INHIBIR FORMACION DE COAGULO EN SERES HUMANOS Y ANIMALES, FORMULACIONES FARMACEUTICAS UTILES EN EL METODO E INTERMEDIOS PARA LOS INHIBIDORES.
ES92310292T 1991-11-12 1992-11-11 Agentes antitromboticos. Expired - Lifetime ES2120993T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79088591A 1991-11-12 1991-11-12

Publications (1)

Publication Number Publication Date
ES2120993T3 true ES2120993T3 (es) 1998-11-16

Family

ID=25152024

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92310292T Expired - Lifetime ES2120993T3 (es) 1991-11-12 1992-11-11 Agentes antitromboticos.

Country Status (19)

Country Link
EP (1) EP0542525B1 (es)
JP (1) JP3159806B2 (es)
KR (1) KR930009993A (es)
CN (1) CN1074438A (es)
AU (2) AU646767B2 (es)
BR (1) BR9204361A (es)
CA (1) CA2082748A1 (es)
CZ (1) CZ333492A3 (es)
DE (1) DE69226152T2 (es)
ES (1) ES2120993T3 (es)
FI (1) FI925124A (es)
HU (1) HUT65858A (es)
IL (1) IL103692A0 (es)
MX (1) MX9206474A (es)
NO (1) NO924326L (es)
NZ (1) NZ245039A (es)
TW (1) TW232686B (es)
YU (1) YU97292A (es)
ZA (1) ZA928581B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5488037A (en) * 1994-03-04 1996-01-30 Eli Lilly And Company Antithrombotic agents
ZA951618B (en) * 1994-03-04 1996-08-27 Lilly Co Eli Antithrombotic agents
US5436229A (en) * 1994-03-04 1995-07-25 Eli Lilly And Company Bisulfite adducts of arginine aldehydes
US5602101A (en) * 1994-03-04 1997-02-11 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5484772A (en) * 1994-03-04 1996-01-16 Eli Lilly And Company Antithrombotic agents
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5885967A (en) * 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
CA2143533A1 (en) * 1994-03-04 1995-09-05 Kenneth D. Kurz Antithrombotic agents
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
JPH09509943A (ja) * 1994-03-04 1997-10-07 イーライ・リリー・アンド・カンパニー 抗血栓剤
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
SK104697A3 (en) * 1995-02-17 1998-11-04 Basf Ag Novel dipeptide amidines as thrombin inhibitors
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
AU7292398A (en) 1997-05-15 1998-12-08 Eli Lilly And Company Antithrombotic compound
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
HUP0100082A3 (en) 1998-01-26 2001-12-28 Abbott Gmbh & Co Kg Thrombin inhibitor, peptide derivatives, pharmaceutical compositions comprising thereof and their use
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
TR200102037T2 (tr) 1999-01-13 2001-10-22 Astrazeneca Ab Yeni amidinobenzilamin türevleri ve trombin engelleyiciler olarak kullanılmaları.
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
WO2001079208A1 (fr) * 2000-04-19 2001-10-25 Kaneka Corporation Nouveau derive d'azetidine et procede de preparation de celui-ci
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
US7795205B2 (en) 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
RU2008139428A (ru) * 2006-03-06 2010-05-20 Хьюмэджин, Инк. (Us) Способ получения рекомбинантного тромбина и фибриногена человека
CN101190895B (zh) * 2006-11-30 2010-05-26 首都医科大学 N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
CN101318933B (zh) * 2007-06-04 2010-08-11 北京大学 具有抗血栓活性的异喹啉化合物、其制备方法及应用
CN102127097A (zh) * 2010-01-15 2011-07-20 首都医科大学 N-(3s-1,2,3,4-四氢异喹啉-3-甲酰基)氨基酸铜络合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4318904A (en) * 1980-04-25 1982-03-09 Research Corporation Peptide affinity labels for thrombin and other trypsin-like proteases
HU192646B (en) * 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides

Also Published As

Publication number Publication date
DE69226152D1 (de) 1998-08-13
AU2831292A (en) 1993-05-13
EP0542525A3 (en) 1994-06-29
JP3159806B2 (ja) 2001-04-23
CN1074438A (zh) 1993-07-21
ZA928581B (en) 1994-05-06
AU2829892A (en) 1993-05-13
HU9203545D0 (en) 1993-01-28
NO924326L (no) 1993-05-14
HUT65858A (en) 1994-07-28
TW232686B (es) 1994-10-21
KR930009993A (ko) 1993-06-21
BR9204361A (pt) 1993-06-01
DE69226152T2 (de) 1998-12-10
EP0542525B1 (en) 1998-07-08
CZ333492A3 (en) 1993-09-15
NZ245039A (en) 1994-12-22
YU97292A (sh) 1995-10-24
CA2082748A1 (en) 1993-05-13
MX9206474A (es) 1993-10-01
NO924326D0 (no) 1992-11-10
EP0542525A2 (en) 1993-05-19
FI925124A0 (fi) 1992-11-11
AU646767B2 (en) 1994-03-03
FI925124A (fi) 1993-05-13
JPH05221964A (ja) 1993-08-31
IL103692A0 (en) 1993-04-04

Similar Documents

Publication Publication Date Title
ES2120993T3 (es) Agentes antitromboticos.
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
ES2070660B1 (es) Un procedimiento para la preparacion de 2,5-damino-3-hidroxihexanos sustituidos, utiles como inhibidores de proteasas retrovirales.
ES514672A0 (es) "un procedimiento para la preparacion de derivados de aminoacidos utiles como agentes antihipertensores".
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
ITFI910071U1 (it) Piastra per osso per la porzione distale dell'omero.
AR002043A1 (es) Utilizacion de agonistas de alfa (1l) para el tratamiento de la incontinencia urinaria.
ES2077948T3 (es) Preparacion para el cuidado externo de la piel.
PA8431301A1 (es) Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion
DK0657428T3 (da) Fremstilling af 3,4,4-trisubstituerede-piperidinyl-N-alkylcarboxylater og mellemprodukter, der er egnede som opioidantagonister
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
DK185785A (da) Steril injektionssproejte navnlig til dentalt brug
ES2094792T3 (es) Uso de compuestos con actividad agonista de receptor 5-ht1a para la inhibicion de la secrecion de acidos gastricos.
ES2128669T3 (es) Metodo para el tratamiento de la ansiedad usando un compuesto de tetrahidropiridina u oxadiazol o tiadiazol azabiciclico.
DK0427026T3 (da) Midler til behandling af fedtdepoter hos mennesker
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
ES2063309T3 (es) Derivados de pirimidina 3-oxido halogenados, su utilizacion para el tratamiento y la prevencion de la caida de los cabellos y para estimular su crecimiento.
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
DK164441C (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
ES2059301T3 (es) Utilizacion de inhibidores de la enzima convertidora de angiotensina para el tratamiento de la aterosclerosis, trombosis y de la enfermedad vascular periferica.
ES2060239T3 (es) Analogos de bis(alquil-sustituido-4-hidroxifeniltio)alcano como inhibidores de la formacion de cataratas.
AR013462A1 (es) Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 542525

Country of ref document: ES